ANI PHARMACEUTICALS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $883.4M | $614.4M | $486.8M | $316.4M | $216.1M |
| Selling, general & administrative | $317.7M | $249.6M | $161.7M | $124.0M | $84.3M |
| Research and development | $51.7M | $44.6M | $34.3M | $22.3M | $11.4M |
| Operating income | $111.1M | $584,000 | $47.0M | -$35.3M | -$39.8M |
| Pretax income | $95.8M | -$22.2M | $19.9M | -$62.7M | -$56.1M |
| Income tax expense | $17.5M | -$3.7M | $1.1M | -$14.8M | -$13.5M |
| Net income | $78.3M | -$18.5M | $18.8M | -$47.9M | -$42.6M |
| Balance Sheet | |||||
| Cash and equivalents | $285.6M | $144.9M | $221.1M | $48.2M | $100.3M |
| Current assets | $753.1M | $528.5M | $519.8M | $344.3M | $321.8M |
| Total assets | $1.4B | $1.3B | $904.4M | $760.1M | $771.6M |
| Current liabilities | $278.1M | $194.5M | $145.5M | $99.4M | $87.5M |
| Total liabilities | $899.7M | $855.9M | $446.8M | $421.5M | $412.9M |
| Stockholders' equity | $540.7M | $403.7M | $432.7M | $313.7M | $333.9M |
| Cash Flow Statement | |||||
| Cash from operations | $185.2M | $64.0M | $119.0M | -$31.2M | $3.3M |
| Depreciation and amortization | $8.9M | $7.4M | $7.5M | $7.4M | $47.3M |
| Stock-based compensation | $37.9M | $29.3M | $20.7M | $14.6M | $10.5M |
| Capital expenditure | $13.8M | $16.2M | $8.9M | $8.9M | $2.6M |
| Free cash flow | $171.4M | $47.8M | $110.1M | -$40.1M | $765,000 |
| Dividends paid | $1.2M | $1.6M | $1.6M | $1.6M | $190,000 |
| Share repurchases | $12.2M | $11.0M | $5.0M | $2.0M | $890,000 |
| Impairments | $767,000 | $7.6M | $0 | $574,000 | $2.4M |
Shares outstanding 22.7M · Free float 60.9%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.